平衡血栓症和出血:在肝硬化相关的血栓细胞减小症中进行抗血栓治疗
Sarah Taylor1, Julie Wang2,3, Hui Yin Lim2,3,4,5,6
1Department of Gastroenterology, Northern Health, Epping, VIC 3076, Australia.
Journal of clinical medicine
|March 14, 2026
概括
肝硬化中的血栓缩复杂化抗凝剂由于出血风险和改变的药理动力学. 直接口服抗凝剂在补偿性肝硬化中表现有前途,但个性化管理是关键.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
背景情况:
- 肝硬化经常导致血小板缺血和复杂的静血性变化.
- 这创造了一个重新平衡的状态,使患者倾向于发生血栓和出血.
- 在肝硬化相关的血小板衰竭中治疗血栓形成是一个重大的临床挑战.
研究的目的:
- 审查有关肝硬化相关的血栓塞栓症的现有证据.
- 要总结这种患者群体的抗血栓治疗选择和挑战.
- 为了确定未来研究的知识差距.
主要方法:
- 对目前有关血栓栓塞性疾病和抗血栓治疗的证据的文献综述.
- 对肝硬化和血小板狭窄症患者抗凝药的挑战进行分析.
- 讨论传统和新型抗凝剂策略.
主要成果:
- 肝硬化与血小板狭窄的抗凝治疗是复杂的,因为药物的药理动力学,凝血测试异常和出血风险.
- 低分子量肝素和维生素K对抗剂是传统的选择.
- 直接口服抗凝剂越来越多地支持补偿性肝硬化患者.
结论:
- 个性化管理至关重要,考虑到肝病的严重程度,血栓性负担,出血风险和门性高血压.
- 需要对最佳血小板值和功能凝固测试进行进一步的前性研究.
- 在肝硬化相关的血小板缺血症中优化抗血小板治疗需要解决关键的知识差距.
相关概念视频
Venous Thrombosis III: Interprofessional Care
449
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
449
Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.2K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.2K
Esophageal Varices-II: Clinical Features and Management
723
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
723
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
Venous Thrombosis IV: Nursing Management
354
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
354
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.5K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K


